Britannia Life Sciences Inc (BLSIF) fair value: what the stock is really worth
As of Sep 21, 2026: fair value of Britannia Life Sciences Inc $0.05, price $0.04, upside +27.6%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Britannia Life Sciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.0001 – $1.98 · fair‑value band $0.0443 – $0.0712 · the $0.0413 price screens below the $0.0527 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Britannia Life Sciences in your weekly email
Every Wednesday you see whether Britannia Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Britannia Life Sciences Inc. engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally. It serves cosmetics, consumer packaged and household goods, and nutraceutical industries. The company is headquartered in Toronto, Canada.
Stock analysis
Britannia Life Sciences Inc (BLSIF) currently trades at $0.0413, while our model-based Fair Value estimate is $0.0527, implying the stock looks roughly 21.6% undervalued today.
Show more
Valuation
Bull case: the Earnings-Based group reads highest at a median of $0.3800 per share, and 5 of the 7 models we run sit above the $0.0413 price.
Bear case: the Asset-Based group reads lowest at $0.0300, and 2 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0443 (bear) to $0.0712 (bull), the price of $0.0413 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Britannia Life Sciences Inc reported revenue of C$369K in FY2025 versus C$1.4M in FY2021, a compound −28.6%/yr. Reported net income was C$7.4M in FY2025.
Key figures
Market cap $9.7M · P/E ratio 1.0 · P/S ratio 20.7 · EPS (TTM) $0.0400 · Net margin 12,994% · Return on equity 67.8% · Return on assets (EBIT) −16.4% · Operating margin −581%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 38% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 28%, BLSIF screens cheaper than that median.
Fair Value models
Bear $0.0443Fair Value $0.0527Bull $0.0712
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.0400 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−28.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−63.0%
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+13.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.3%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → −548%
Compare Britannia Life Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Top 25%
Fair Value upside+28% · Top 25%
Profitability
Return on equity (TTM)68% · Top 25%
Return on assets−7% · Above median
Growth and dividend
Revenue growth−61% · Bottom 25%
Balance sheet
Debt / equity0.25× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Britannia Life Sciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/BLSIF
Frequently asked questions
Is Britannia Life Sciences Inc (BLSIF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0527 versus a price of $0.0413, about +28% upside (undervalued).
What is the fair value of BLSIF?
Our model-based fair value for Britannia Life Sciences Inc is $0.0527 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.0413.
What is the quality score of BLSIF?
Britannia Life Sciences Inc has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Britannia Life Sciences Inc (BLSIF)?
Our model-based price target is the fair value of $0.0527 (as of Sep 24, 2026) from 7 valuation models. Cautious scenario $0.0443, optimistic scenario $0.0712. It is a calculation from audited fundamentals, not an analyst target.
What is the Britannia Life Sciences Inc stock forecast for 2026?
Our models put fair value at $0.0527, about +28% upside versus a price of $0.0413 (undervalued). Cautious scenario $0.0443, optimistic scenario $0.0712. The calculation is refreshed regularly with new filings.
What is the revenue of Britannia Life Sciences Inc (BLSIF)?
Britannia Life Sciences Inc reported trailing-twelve-month revenue of about C$158K (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Britannia Life Sciences Inc (BLSIF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Britannia Life Sciences Inc it is $0.0527 per share (as of Sep 24, 2026), against a price of $0.0413. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Britannia Life Sciences Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BLSIF trades below its calculated fair value: price $0.0413, fair value $0.0527, a gap of about +28% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLSIF?
No. The price is what the market pays today ($0.0413); the fair value is what the company's own numbers justify ($0.0527). For Britannia Life Sciences Inc the two are $0.0114 per share apart. That gap is exactly why we show both numbers side by side.
How much is Britannia Life Sciences Inc worth?
The market values Britannia Life Sciences Inc at about $9.7M (market capitalisation, as of Sep 24, 2026). Per share that is $0.0413; our models calculate a fair value of $0.0527 per share.
What do the bullish and bearish scenarios say about BLSIF?
Our models span a range for Britannia Life Sciences Inc: cautious scenario $0.0443, base $0.0527, optimistic $0.0712 per share (as of Sep 24, 2026, price $0.0413). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLSIF?
Britannia Life Sciences Inc trades at a price-to-earnings ratio of 1.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0527 is built from several models across several years. Other multiples: P/B 1.6, P/S 61.7.
How solid is the balance sheet of Britannia Life Sciences Inc (BLSIF)?
Balance-sheet figures for Britannia Life Sciences Inc (as of Sep 24, 2026): return on equity 67.8%, debt of 0.25 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is BLSIF from its 52-week high?
Britannia Life Sciences Inc trades at $0.0413, about 38% below its 52-week high of $0.0666 and 38% above the low of $0.0300 (as of Sep 21, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0527 is for.
Which stocks are comparable to Britannia Life Sciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Britannia Life Sciences Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0413, calculated fair value $0.0527 (+28%), Quality Score 57/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLSIF calculated?
We run Britannia Life Sciences Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0527, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Britannia Life Sciences Inc currently trades 28 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Britannia Life Sciences Inc (BLSIF)?
The closing price on Sep 21, 2026 was $0.0413. Our model-based fair value is $0.0527, about +28% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Britannia Life Sciences Inc right now?
The price is below even our cautious bear case ($0.0443). The market is more pessimistic than our downside scenario. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Britannia Life Sciences Inc
How large is the market capitalisation of Britannia Life Sciences Inc (BLSIF)?
The market capitalisation of Britannia Life Sciences Inc is $9.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Britannia Life Sciences Inc (BLSIF)?
The price-to-sales ratio of Britannia Life Sciences Inc is 20.7 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Britannia Life Sciences Inc (BLSIF)?
Earnings per share at Britannia Life Sciences Inc are $0.0400 (price ÷ EPS = P/E 1.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Britannia Life Sciences Inc (BLSIF)?
The net margin of Britannia Life Sciences Inc is 12,994% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Britannia Life Sciences Inc (BLSIF)?
The return on equity (ROE) of Britannia Life Sciences Inc is 67.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Britannia Life Sciences Inc (BLSIF)?
On an EBIT basis the return on assets of Britannia Life Sciences Inc is −16.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Britannia Life Sciences Inc (BLSIF)?
The operating margin of Britannia Life Sciences Inc is −581% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Britannia Life Sciences Inc (BLSIF)?
Revenue at Britannia Life Sciences Inc is growing −61.2% versus a year earlier (3y avg −63.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Britannia Life Sciences Inc (BLSIF)?
Earnings per share at Britannia Life Sciences Inc are growing −33.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Britannia Life Sciences Inc (BLSIF) generate?
The free cash flow of Britannia Life Sciences Inc is −C$2.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Britannia Life Sciences Inc (BLSIF) carry?
The net debt of Britannia Life Sciences Inc is C$5.6M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Britannia Life Sciences Inc in the live analysis
One click puts Britannia Life Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026